Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphocholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | AKT1 | P31749 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | PRKCH | P24723 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphocholine SCHEMBL7646155 | 0.98 | LMNA (0.52) | LMNAAKT1ADRA1AESR1ADORA3 | |
| Phosphocholine SCHEMBL9447039 | 0.98 | LMNA (0.55) | LMNAAKT1ADRA1AESR1ADORA3 | |
| Phosphocholine SCHEMBL18192302 | 0.98 | LMNA (0.55) | LMNAAKT1ADRA1AESR1ADORA3 | |
| Phosphocholine SCHEMBL5330902 | 0.96 | LMNA (0.50) | LMNAAKT1ADRA1AESR1ADORA3 | |
| Phosphocholine SCHEMBL10717808 | 0.95 | LMNA (0.53) | LMNAAKT1ADRA1AESR1ADORA3 | |
| Phosphocholine SCHEMBL9447079 | 0.95 | LMNA (0.53) | LMNAAKT1ADRA1AESR1ADORA3 | |
| Phosphocholine SCHEMBL9447028 | 0.95 | LMNA (0.53) | LMNAAKT1ADRA1AESR1ADORA3 | |
| Phosphocholine SCHEMBL9335813 | 0.87 | SMN1; SMN2 (0.51) | LMNAAKT1ADRA1AESR1ADORA3 | |
| Phosphocholine SCHEMBL15525300 | 0.84 | SMN1; SMN2 (0.45) | LMNAAKT1ADRA1AESR1ADORA3 | |
| Phosphocholine SCHEMBL3485572 | 0.82 | CHRM5 (0.68) | LMNAAKT1ADRA1AESR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115466406-B | PH-UCST responsive lignin-based zwitterionic compound and preparation method thereof and method for recycling cellulase at room temperature | 华南理工大学 | 2023-08-22 | — | — | CN | claimed |
| CN-115466406-A | PH-UCST response type lignin-based zwitterionic compound, preparation method thereof and method for recovering cellulase at room temperature | 华南理工大学 | 2022-12-13 | — | — | CN | claimed |
| CN-110759942-A | Method for industrially producing choline alfoscerate | 江苏恒正合生命科学有限公司 | 2020-02-07 | — | — | CN | claimed |
| CN-104004040-B | A kind of method utilizing oxalyl chloride to prepare CITICOLINE SODIUM | FUZHOU PHARMACEUTICAL CO., LTD., TONGYINBI GROUP (CN) | 2016-01-27 | — | — | CN | claimed |
| CN-104031105-B | Method for preparing citicoline sodium | ZHEJIANG TIANRAN DRUG RES CO LTD | 2015-07-15 | — | — | CN | claimed |
| CN-104031105-A | Method for preparing citicoline sodium | ZHEJIANG TIANRAN DRUG RES CO LTD | 2014-09-10 | — | — | CN | claimed |
| CN-104004040-A | Method for preparing citicoline sodium by utilizing oxalyl chloride | YU ZHONGHUA | 2014-08-27 | — | — | CN | claimed |
| JP-61282303-A | — | — | None | — | — | JP | disclosed |
| CN-119955879-A | Method for synthesizing citicoline by biological enzyme | 拓新药业集团股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025017570-A1 | SYNERGISTIC BIOACTIVE COMPOSITION FOR MODULATING CHOLINE DEHYDROGENASE (CHD) ACTIVITY | Celagenex Research (India) Pvt. Ltd. (IN) | 2025-01-23 | — | — | WO | disclosed |
| CN-113816991-B | Preparation method of choline calcium chloride phosphate | 拓新药业集团股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-115466406-B | PH-UCST responsive lignin-based zwitterionic compound and preparation method thereof and method for recycling cellulase at room temperature | 华南理工大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-116284187-A | Method for synthesizing urine phosphorylcholine in citicoline injection | 山东玉满坤生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-102304150-A | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2012-01-04 | — | — | CN | disclosed |
| CN-101084231-B | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2011-08-24 | — | — | CN | disclosed |
| CN-101084231-A | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2007-12-05 | — | — | CN | disclosed |
| CN-1809565-A | Pyrrolodihydroisoquinolines for the treatment of cancer | ALTANA PHARMA AG (DE) | 2006-07-26 | — | — | CN | disclosed |
| CN-1556863-A | Methods and compositions relating to HPV-associated precancerous and cancerous growths, including CIN | 得克萨斯大学体系董事会 | 2004-12-22 | — | — | CN | disclosed |
| WO-2003026489-A2 | BIOPOLYMER AND BIOPOLYMER-CELL COMPOSITIONS FOR NERVE TISSUE REPAIR | UNIVERSITY OF FLORIDA (US) | 2003-04-03 | — | — | WO | disclosed |
| JP-S61282303-A | GROWTH REGULATOR FOR SUGAR CANE | MITSUBISHI GAS CHEM CO INC | 1986-12-12 | — | — | JP | disclosed |